Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy
使用新型口服生物可利用小分子抑制剂 RO9021 选择性抑制脾脏酪氨酸激酶 (SYK)，影响各种先天性和适应性免疫反应：对 SYK 抑制剂在自身免疫性疾病治疗中的意义
期刊:Arthritis Research & Therapy
影响因子:4.4
doi:10.1186/ar4329
Cheng Liao, Jonathan Hsu, Yong Kim, Dong-Qing Hu, Daigen Xu, Jun Zhang, Achal Pashine, John Menke, Toni Whittard, Natasha Romero, Theresa Truitt, Michelle Slade, Christine Lukacs, Johannes Hermann, Mingyan Zhou, Matthew Lucas, Satwant Narula, Julie DeMartino, Seng-Lai Tan
